Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alkermes Plc (NQ: ALKS )

24.05 -0.21 (-0.87%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,001,642
Open 24.35
Bid (Size) 24.00 (7)
Ask (Size) 26.99 (3)
Prev. Close 24.26
Today's Range 24.04 - 24.46
52wk Range 22.01 - 33.71
Shares Outstanding 166,121,384
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Investors should take notice of NASDAQ:ALKS—it offers a great deal for the fundamentals it presents.
ALKERMES PLC (NASDAQ:ALKS) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
7 Analysts Assess Alkermes: What You Need To Know
Via Benzinga

Performance

YTD
-15.97%
-15.97%
1 Month
-10.03%
-10.03%
3 Month
-10.16%
-10.16%
6 Month
-1.88%
-1.88%
1 Year
-23.33%
-23.33%

More News

Read More
Exploring growth characteristics of ALKERMES PLC (NASDAQ:ALKS).
Via Chartmill
ALKS Stock Earnings: Alkermes Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Investors should take notice of NASDAQ:ALKS—it offers a great deal for the fundamentals it presents.
Via Chartmill
Exploring growth characteristics of ALKERMES PLC (NASDAQ:ALKS).
Via Chartmill
Alkermes' Sleeping Disorder Studies' Data Look Excellent, Analyst Says
Via Benzinga
Breaking Down Alkermes: 5 Analysts Share Their Views
Via Benzinga
Is NASDAQ:ALKS suited for growth investing?
Via Chartmill
When you look at NASDAQ:ALKS, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill
The Analyst Verdict: Alkermes In The Eyes Of 4 Experts
Via Benzinga
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Amicus Therapeutics Stock Sees RS Rating Improve To 74
Via Investor's Business Daily
NASDAQ:ALKS stands out as a stock that provides good value for the fundamentals it showcases.
Via Chartmill
Exploring NASDAQ:ALKS's growth characteristics.
Via Chartmill
Earnings Scheduled For February 15, 2024
Via Benzinga
Alkermes's Earnings Outlook
Via Benzinga
Is NASDAQ:ALKS suited for growth investing?
Via Chartmill
Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat
Via Investor's Business Daily
Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark
Via Investor's Business Daily
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024
Via InvestorPlace
Alkermes Stock Gets RS Rating Upgrade; Profits Surge
Via Investor's Business Daily
CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+
Via Investor's Business Daily
NASDAQ:ALKS is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill
7 Biotech Stocks Fighting America’s Deadliest Diseases
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.